Study on the correlation between serum MG53 level and coronary artery calcification

doi:10.16138/j.1673-6087.2024.05.03

Abstract

Abstract:

Objective To study the correlation between serum MG53 level and coronary artery calcification (CAC), and the correlation between serum MG53 level and the prognosis of patients with CAC. Methods A total of 195 patients admitted to the Department of Cardiovascular Medicine of Ruijin Hospital， Shanghai Jiao Tong University School of Medicine from 2016 to 2018 due to chest distress and other discomforts were selected. CAC was confirmed by coronary CT angiography (CTA) in all patients. Agatston integral was used to calculate CAC score, and serum MG53 level was detected by enzyme-linked immunosorbent assay. Patients were followed up for 5 years, and the endpoint events were recorded. Patients were grouped according to CAC score and serum MG53 level. Logistic regression was used to analyze the correlation between serum MG53 level and CAC level. Kaplan-Meier curve and COX proportional risk model were used to analyze the effect of serum MG53 level on the prognosis of CAC patients. The R software (4.2.2 version) was used to calculate the best cut-off value of serum MG53 level for predicting end-point events. Results Compared with the low-risk group，the serum MG53 level in the high-risk group was significantly lower [57.717 (28.548，139.965) pg/mL vs 33.553 (13.509，56.952) pg/mL, P<0.001]. Serum MG53 level was independently associated with the severity of CAC (OR=0.984, 95%CI：0.971-0.994, P<0.007). The risk of cardiovascular events was significantly increased in patients with low MG53 levels (OR=0.282, 95%CI：0.160-0.498, P<0.001). The cutoff value of MG53 was calculated as 18.36 pg/mL. Conclusions Serum MG53 level may be related to the degree of CAC and the prognosis of patients，suggesting that serum MG53 level may be a biomarker for predicting CAC and the prognosis of patients.

Key words: Coronary artery calcification, MG53, Coronary artery calcium score, Biomarkers, Prognosis, CT angiography

CLC Number:

R543.3

ZHANG Yu, ZHA Qing, YANG Ling, YE Jiawen, YANG Ke, LIU Yan. Study on the correlation between serum MG53 level and coronary artery calcification[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(05): 303-309.

Figures/Tables 8

Table 1

Baseline characteristics of two groups of patients[$\bar{x}\pm s$/n(%)/M(Q1, Q3)]

项目	低风险组 (n=66)	高风险组 (n=129)	t/U/χ²	P
年龄(岁)	59.00(53.00,66.00)	67.00(61.00,75.00)	-4.889	<0.001
男性[n(%)]	39(59.1)	99(76.7)	6.578	0.010
BMI(kg/m²)	25.403±3.218	25.421±3.235	-0.036	0.972
吸烟[n(%)]	24(36.4)	69(53.5)	5.133	0.023
心率（次/min）	78(68,88)	76(70,84)	0.263	0.794
收缩压(mmHg)	130.606±17.203	135.341±19.581	-1.655	0.100
舒张压(mmHg)	73.591±10.047	74.829±10.861	-0.769	0.443
高血压[n(%)]	36(54.5)	94(72.9)	6.596	0.010
糖尿病[n(%)]	16(24.2)	50(38.8)	4.110	0.043
慢性肾脏病[n(%)]	1(1.5)	6(4.7)	1.241	0.265
hsCRP（mg/L）	3.689±9.875	2.591±6.299	0.774	0.440
血红蛋白（g/L）	136.0(124.0,144.0)	135.0(124.0,145.0)	0.361	0.719
血小板（×10⁹/L）	177.0(146.0,205.0)	172.0(145.0,206.0)	0.043	0.967
空腹血糖（mmol/L）	5.506±1.296	5.943±2.073	-1.411	0.160
HbA_1c（%）	5.911±0.774	6.339±1.220	-2.508	0.013
TC(mmol/L)	3.66(3.02,4.18)	4.20(3.66,5.28)	-4.362	<0.001
TG(mmol/L)	1.32(1.00,1.74)	1.42(1.04,1.99)	-1.243	0.214
LDL-C（mmol/L）	2.03(1.49,2.46)	2.67(2.17,3.44)	-5.740	<0.001
HDL-C（mmol/L）	1.37(1.22,1.51)	1.09(0.93,1.29)	6.544	<0.001
LP(a)（mmol/L）	0.12(0.07,0.32)	0.14(0.08,0.30)	-0.236	0.814
eGFR(ml/min)	85.203±17.008	78.278±17.753	2.578	0.010
Ca²⁺(mmol/L)	2.240(2.170,2.290)	2.240(2.170,2.310)	-0.370	0.712
P(mmol/L)	1.140(1.010,1.250)	1.120(1.020,1.230)	0.550	0.583
D-二聚体(mg/L)	0.325±0.382	0.881±3.295	-1.359	0.176
MG53（pg/mL）	58.717(28.548,139.965)	33.553(13.509,56.952)	4.840	<0.001
LVEF(%)	66.00(64.00,69.00)	64.00(57.00,68.00)	3.125	0.002
LVDD(mm)	48.00(46.00,52.00)	49.00(46.00,51.00)	-0.046	0.965
LVSD(mm)	30.00(29.00,33.00)	31.00(29.00,34.00)	-0.719	0.471
他汀类药物[n(%)]	42(63.6)	120(93.0)	26.819	<0.001
抗血小板药[n(%)]	44(66.7)	119(92.2)	20.830	<0.001
CCB[n(%)]	18(27. 3)	46(35.7)	1.393	0.238
利尿剂[n(%)]	28(42.4)	28(21.7)	9.156	0.002
ACEI/ARB[n(%)]	33(50.0)	78(60.5)	1.950	0.163
β受体阻滞剂[n(%)]	51(77.3)	89(69.0)	1.478	0.224
降糖药[n(%)]	11(16.7)	39(30.2)	4.214	0.040

Table 1

Table 2

Figure 1

Table 3

Figure 2

Table 4

Figure 3

Figure 4

References 20

[1]	Hashmi S, Shah PW, Aherrahrou Z, et al. Beyond the basics: unraveling the complexity of coronary artery calcification[J]. Cells, 2023, 12(24):2822.
[2]	Mohan J, Bhatti K, Tawney A, et al. Coronary artery calcification[M/OL]. 2023. https://www.ncbi.nlm.nih.gov/books/NBK519037/.
[3]	Ji B, Liu XB. Coronary artery calcification: concepts and clinical applications[J]. Ann Med Surg (Lond), 2024, 86(5):2848-2855.
[4]	Song R, Peng W, Zhang Y, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders[J]. Nature, 2013, 494(7437):375-379.
[5]	Jiang W, Liu M, Gu C, et al. The pivotal role of mitsugumin 53 in cardiovascular diseases[J]. Cardiovasc Toxicol, 2021, 21(1):2-11.
[6]	Feng H, Shen H, Robeson MJ, et al. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage[J]. Diabetes, 2022, 71(2):298-314.
[7]	Cao CM, Zhang Y, Weisleder N, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning[J]. Circulation, 2010, 121(23):2565-2574.
[8]	Pagliaro P, Penna C. Cardiac postconditioning[J]. Antioxid Redox Signal, 2011, 14(5):777-779.
[9]	Han X, Chen D, Liufu N, et al. MG53 protects against sepsis-induced myocardial dysfunction by upregulating peroxisome proliferator-activated receptor-α[J]. Oxid Med Cell Longev, 2020, 2020:7413693.
[10]	Xie H, Wang Y, Zhu T, et al. Serum MG53/TRIM72 is associated with the presence and severity of coronary artery disease and acute myocardial infarction[J]. Front Physiol, 2020, 11:617845.
[11]	Xie H, Yan Z, Feng S, et al. Prognostic value of circulating MG53 levels in acute myocardial infarction[J]. Front Cardiovasc Med, 2020, 7:596107.
[12]	van der Aalst CM, Denissen SJAM, Vonder M, et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial[J]. Eur Heart J Cardiovasc Imaging, 2020, 21(11):1216-1224.
[13]	Zhao Y, Qian Y, Sun Z, et al. Role of PI3K in the progression and regression of atherosclerosis[J]. Front Pharmacol, 2021, 12:632378.
[14]	Hao N, Zhou Z, Zhang F, et al. Interleukin-29 accelerates vascular calcification via JAK2/STAT3/BMP2 signaling[J]. J Am Heart Assoc, 2023, 12(1):e027222.
[15]	Huang H, Feng H, Zhuge D. M1 macrophage activated by notch signal pathway contributed to ventilator-induced lung injury in chronic obstructive pulmonary disease model[J]. J Surg Res, 2019, 244:358-367. doi: S0022-4804(19)30456-1 pmid: 31323391
[16]	Liu C, Li B, Tang K, et al. Aquaporin 1 alleviates acute kidney injury via PI3K-mediated macrophage M2 polarization[J]. Inflamm Res, 2020, 69(5):509-521. doi: 10.1007/s00011-020-01334-0 pmid: 32179955
[17]	Kang JH, Kawano T, Murata M, et al. Vascular calcification and cellular signaling pathways as potential therapeutic targets[J]. Life Sci, 2024, 336:122309.
[18]	Chen X, Su J, Feng J, et al. TRIM72 contributes to cardiac fibrosis via regulating STAT3/Notch-1 signaling[J]. J Cell Physiol, 2019, 234(10):17749-17756. doi: 10.1002/jcp.28400 pmid: 30820965
[19]	Wang Y, Zhou H, Wu J, et al. MG53 alleviates hypoxia/reoxygenation-induced cardiomyocyte injury by succinylation and ubiquitination modification[J]. Clin Exp Hypertens, 2023, 45(1):2271196.
[20]	Li Z, Dai R, Chen M, et al. p55γ degrades RIP3 via MG53 to suppress ischaemia-induced myocardial necroptosis and mediates cardioprotection of preconditioning[J]. Cardiovasc Res, 2023, 119(14):2421-2440.

因素	β	SE	Wald χ²	OR（95%CI）	P
年龄(每增加 1岁)	0.068	0.015	20.603	1.070(1.039~1.102)	<0.001
男性	0.826	0.326	6.431	2.285(1.207~4.326)	0.011
目前吸烟	0.699	0.311	5.063	2.012(1.094~3.701)	0.024
高血压	0.806	0.317	6.472	2.238(1.203~4.164)	0.011
糖尿病	0.682	0.339	4.04	1.978(1.017~3.846)	0.044
抗血小板药物使用史	1.783	0.42	18.012	5.950(2.611~13.558)	<0.001
他汀类药物使用史	2.031	0.43	22.297	7.619(3.280~17.699)	<0.001
降糖药使用史	0.773	0.382	4.1	2.167(1.025~4.580)	0.043
HDL-C（每升高 1 mmol/L）	-3.48	0.641	-29.496	0.031(0.009~0.108）	<0.001
LDL-C（每升高 1 mmol/L）	1.051	0.219	22.992	2.859(1.861~4.393）	<0.001
eGFR（每升高 1 mL/min）	-0.023	0.009	-6.325	0.977(0.960~0.995）	0.012
MG53（每升高 1 pg/mL）	-0.015	0.003	-19.448	0.985(0.979~0.992）	<0.001

指标	HR(95% CI)	P
未调整	0.282(0.16~0.498)	<0.001
模型1	0.34(0.191~0.605)	<0.001
模型2	0.4(0.217~0.738)	0.003

指标	CACS≤100 AU		CACS>100 AU
指标	HR(95% CI)	P	HR(95% CI)	P
未调整	0.377 (0.09~1.577)	0.181	0.296 (0.158~0.552)	<0.001
模型1	0.254 (0.052~1.254)	0.093	0.333 (0.175~0.631)	0.001
模型2	0.24 (0.02~2.822)	0.257	0.369 (0.184~0.739)	0.005